Health Press Release – Newsletter for December 9, 2010

New NIH Guidelines Advocate ImmunoCAP Blood Test to Improve Diagnosis of Food Allergy

UPPSALA, Sweden, December 8, 2010 – New guidelines on diagnosis and management of food allergy issued by the
National Institute of Allergy and Infectious Diseases a part of NIH, supports
a broader use of blood test to improve current clinical practice.
Phadia's ImmunoCAP is recognized for its superior predictive values compared
to other systems. It provides precise, quantitative …. Original article  : New NIH Guidelines Advocate ImmunoCAP Blood Test to Improve Diagnosis of Food Allergy.

The Binding Site Appoints Charles de Rohan as Chief Executive Officer

BIRMINGHAM, England, December 8, 2010 – The Binding Site Corporation Limited ("Binding Site" or "the
Company"), a privately-owned specialist U.K. diagnostics company, today
announces the appointment of Charles de Rohan as Chief Executive Officer.

Charles de Rohan has worked in the diagnostic industry for
more than 17 years and brings significant experience to the … Read the original article on Gaea Times at : The Binding Site Appoints Charles de Rohan as Chief Executive Officer.

Informex and CMS Pharma Present Inaugural CEO Summit of Pharma Manufacturing

First annual CEO Summit will provide forum for senior industry executives to discuss business strategies and trends in Custom Manufacturing of pharmaceutical ingredients

PRINCETON, New Jersey and INGELHEIM, Germany, December 8, 2010 – Informex, the leading meeting place for buyers and sellers of high-value
chemistry for a broad range of applications, and CMS Pharma, the trusted … Read more : Informex and CMS Pharma Present Inaugural CEO Summit of Pharma Manufacturing.

AVESTHAGEN’s First Biosimilar Molecule AVDESP(TM) Completes Clinical Batch Manufacturing in Malaysia, to Move to Clinical Trials

BANGALORE, India, December 8, 2010 – AVESTHAGEN LIMITED, a leading knowledge based life sciences
company pioneering the convergence between Food, Pharma and Population
Genetics, today announced the completion of manufacturing of the clinical
grade material of its first biosimilar molecule- AVDESP(TM) (biosimilar to
Darbepoetin alfa), which will now be moving into Clinical Trials. Inno
Biologics, Malaysia's biopharma CMO has … Original source on Gaea Times at : AVESTHAGEN's First Biosimilar Molecule AVDESP(TM) Completes Clinical Batch Manufacturing in Malaysia, to Move to Clinical Trials.

Elsevier Enables its e-Books to Read Aloud, Increasing Access for People With Print Disabilities

Text-to-Speech Option Enabled for All Elsevier ePub Book Titles
AMSTERDAM, December 8, 2010 – Elsevier, the world-leading publisher of scientific, technical and
medical information products and solutions, announced today that it has
enabled the text-to-speech option on all of its ePub book titles. The
text-to-speech function enables an e-book to read aloud. This will facilitate
access by readers who … Original article on : Elsevier Enables its e-Books to Read Aloud, Increasing Access for People With Print Disabilities.

/C O R R E C T I O N – Phadia/

UPPSALA, Sweden, December 8, 2010 – In the news release, "New NIH Guidelines Advocate ImmunoCAP Blood Test to
Improve Diagnosis of Food Allergy" issued on 8 Dec 2010 10:56 GMT, by
Phadia over PR Newswire, please note that the link after the first paragraph
has been updated to:
(Logo: www.newscom.com/cgi-bin/prnh/20101208/425503 )
Complete, updated release follows:

New …. Original source  : /C O R R E C T I O N — Phadia/.

NNIT Buys ChannelCRM to Better Service Pharma Businesses

NNIT Buys ChannelCRM – a Specialised Vendor of CRM and Industry Specific xRM Solutions

COPENHAGEN, December 8, 2010 – NNIT has bought Danish software house ChannelCRM in order to further
develop our Customer Relationship Management (CRM) offerings devoted to the
pharmaceutical industry.
(Logo: www.newscom.com/cgi-bin/prnh/20101005/412747 )
The pharmaceutical industry demands both …. Source article  : NNIT Buys ChannelCRM to Better Service Pharma Businesses.